Medication induced osteonecrosis of jaw: A detailed review

References

1. Laputková G, Talian I, Schwartzová V. Medication-related osteonecrosis of the jaw: a systematic review and a bioinformatic analysis. Int J Mol Sci . 2023;24(23):16745. https://doi.org/10.3390/ijms242316745
   [Google Scholar]
2. Pardo-Zamora G, Martínez Y, Moreno JA, Ortiz-Ruíz AJ. Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series. Int J Environ Res Public Health. 2021;18(3):1018. https://doi.org/10.3390/ijerph18031018
   [Google Scholar]
3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7. https://doi.org/10.1016/s0278-2391(03)00720-1
   [Google Scholar]
4. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg. 2009;67(5 Suppl):13–8. https://doi.org/10.1016/j.joms.2008.10.005
   [Google Scholar]
5. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al.; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56. https://doi.org/10.1016/j.joms.2014.04.031
   [Google Scholar]
6. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom. 2017;20(1):8–24. https://doi.org/10.1016/j.jocd.2016.09.005
   [Google Scholar]
7. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis. 2018;24(4):527–36. https://doi.org/10.1111/odi.12708
   [Google Scholar]
8. Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Woo SB. Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol. 2013;49(9):977–83. https://doi.org/10.1016/j.oraloncology.2013.05.012
   [Google Scholar]
9. Jung S, Kim J, Park JH, Kim KY, Kim HJ, Park W. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients. Sci Rep. 2022;12(1):8641. https://doi.org/10.1038/s41598-022-11615-9
   [Google Scholar]
10. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41(2):183–90. https://doi.org/10.1007/s12020-011-9580-0
    [Google Scholar]
11. Drescher W, Schlieper G, Floege J, Eitner F. Steroid-related osteonecrosis--an update. Nephrol Dial Transplant. 2011;26(9):2728–31. https://doi.org/10.1093/ndt/gfr212
    [Google Scholar]
12. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008;9(12):1166–72. https://doi.org/10.1016/S1470-2045(08)70305-X
    [Google Scholar]
13. Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent. 2016;6(2):97–104. https://doi.org/10.4103/2231-0762.178742
    [Google Scholar]
14. Johnston CB, Dagar M. Osteoporosis in older adults. Med Clin North Am. 2020;104(5):873–84. https://doi.org/10.1016/j.mcna.2020.06.004
    [Google Scholar]
15. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62. https://doi.org/10.1056/NEJMcp1513724
    [Google Scholar]
16. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835–41. https://doi.org/10.1210/en.2003-0990
    [Google Scholar]
17. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006;147(12):5592–9. https://doi.org/10.1210/en.2006-0459
    [Google Scholar]
18. Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 2019;4(3):85–97.https://doi.org/10.1302/2058-5241.4.180036
    [Google Scholar] 104 Durge and Das /Journal of Oral Medicine, Oral Surgery, Oral Pathology and Oral Radiology 2025;11(3):98–104
19. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol. 2005;32(11):1123–8. https://doi.org/10.1111/j.1600-051X.2005.00842.x
    [Google Scholar]
20. Thumbigere-Math V, Michalowicz BS, Hodges JS, Tsai ML, Swenson KK, Rockwell L, et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol. 2014;85(2):226–33. https://doi.org/10.1902/jop.2013.130017
    [Google Scholar]